Global Varicocele Treatment Market Size, Share, Forecast Report, 2020-2027

Varicocele is the enlargement of the veins within the scrotum. This is most common in younger male, aged from 15-25 and occurs in approximately one in six males.

Increasing prevalence of varicocele, increasing awareness of the disease, rising healthcare expenditure, advanced diagnosis and treatment options are driving the growth of global varicocele treatment market.

Global varicocele treatment market is expected to grow at the CAGR of ~6.2% during the forecast period and is estimated to reach USD 617.5 million by 2023.
Segments:

Global Varicocele treatment market has been segmented on the basis of grade which comprises of grade I, grade II, grade III, and others.

On the basis of diagnosis it is segmented into physical exam, imaging test, and others. Imaging test further sub-segmented into thermography, scrotal ultrasound, and others

On the basis of treatments, the market has been segmented into varicocele repair, varicocele embolization, medication, and others. Varicocele repair is sub-segmented into open surgery, laparoscopic surgery, percutaneous embolization, and others. Medication is sub-segmented into painkillers, and others. Painkillers includes acetaminophen, ibuprofen, and others.

On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others.
Key players for global Varicocele treatment market:

Some of the key players in this market are: Bayer (Germany), Depomed, Inc. (US), GlaxoSmithKline plc. (UK), INSYS THERAPEUTICS, INC. (US), Janssen Global Services, LLC (Belgium) Mylan N.V. (US), Novartis AG (Switzerland), PurduePharma (US), Pfizer Inc. (US), and others.